News Perspectives

New Drugs Lower LDL, May Protect Heart

A new type of drug lowers cholesterol and may also reduce heart attack and stroke rates, study results show. The 2 new studies look at drugs known as monoclonal antibodies. Both of the study drugs work by shutting down a protein in the liver. The larger study included 4,465 people. They were randomly divided into 2 groups. One group got injections of evolocumab every 2 weeks or every month. People also got standard treatment to lower LDL ("bad cholesterol"). Usually this was a statin drug. The other group got standard treatment only. In the next year, LDL fell 61% more in the evolocumab group than in the standard-treatment group. About 2% of the statin-only group died or had a heart attack, stroke or related event during the study. The rate was 1% in the group taking the new drug. The other study included 2,341 people.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In